trending Market Intelligence /marketintelligence/en/news-insights/trending/hviya3qq_sy1OPkGGWGAfQ2 content esgSubNav
In This List

Sun Pharma recalls children's allergy drug from US, Puerto Rico markets

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Sun Pharma recalls children's allergy drug from US, Puerto Rico markets

Sun Pharmaceutical Industries Ltd.'s U.S. arm is recalling 13,200 bottles of children's cetirizine hydrochloride chewable tablets from the U.S. and Puerto Rico markets, according to an enforcement report by the U.S. FDA.

The ongoing class III recall by Sun Pharmaceutical Industries Inc. is for the 5 mg tablets, made at the company's Halol plant in Gujarat, India, because of failed tablet/capsule specifications.

The tablets are used for preventing or treating certain symptoms of hay fever and other upper respiratory allergies.